Abstract | BACKGROUND/AIMS: METHODS: RESULTS: Twenty-nine patients (83%) completed 144 weeks. Serum HBV DNA declined from a baseline 9.76 log10 copies/mL (median) to 4.68, 5.24, and 5.90 log10 copies/mL at weeks 48, 96, and 144, respectively (P<0.0001 at all time points). Seven patients (25%) achieved HBV DNA<2.3 log10 copies/mL. No adefovir-associated resistance mutations in HBV DNA polymerase or HIV-1 reverse transcriptase were detected. ALT declined from 81 IU/L (median) at baseline by -16.0, -44.5, and -46.0 IU/L at week 48, 96 and 144, respectively (P=<0.05, respectively), and normalized in 71% of patients (20 of 28) by week 144. Two patients developed antibodies against HB ' e' antigen by week 48. No serious adverse events related to adefovir dipivoxil occurred during the study, and HIV-1 RNA and CD4+ cell counts were stable. CONCLUSIONS: Treatment with adefovir dipivoxil for 144 weeks was well tolerated and resulted in significant and sustained reductions in HBV DNA and ALT in HIV/HBV co-infected patients. Efficacy increased with treatment duration, with no loss of viral suppression.
|
Authors | Yves Benhamou, Vincent Thibault, Pamela Vig, Vincent Calvez, Anne-Genevieve Marcelin, Marie-Hélène Fievet, Graeme Currie, Chuy G Chang, Lu Biao, Shelly Xiong, Carol Brosgart, Thierry Poynard |
Journal | Journal of hepatology
(J Hepatol)
Vol. 44
Issue 1
Pg. 62-7
(Jan 2006)
ISSN: 0168-8278 [Print] Netherlands |
PMID | 16274835
(Publication Type: Comparative Study, Journal Article)
|
Chemical References |
- Antiviral Agents
- Organophosphonates
- RNA, Viral
- Lamivudine
- Adenine
- adefovir dipivoxil
|
Topics |
- AIDS-Related Opportunistic Infections
(drug therapy, virology)
- Adenine
(analogs & derivatives, therapeutic use)
- Adult
- Antiviral Agents
(therapeutic use)
- Drug Resistance, Viral
- Female
- Follow-Up Studies
- HIV-1
(drug effects, genetics)
- Hepatitis B virus
(genetics, immunology)
- Hepatitis B, Chronic
(drug therapy, virology)
- Humans
- Lamivudine
(therapeutic use)
- Male
- Organophosphonates
(therapeutic use)
- Pilot Projects
- Polymerase Chain Reaction
- Prospective Studies
- RNA, Viral
(analysis)
- Treatment Outcome
|